Please login to the form below

Not currently logged in
Email:
Password:

James Murdoch to step down from GSK's board

Announcement follows 2011’s damaging revelations of phone hacking at UK newspaper the News of the World

James Murdoch will step down from GlaxoSmithKline's (GSK) board of directors after the pharma company's annual general meeting later this year.

Murdoch is chairman and chief executive of the News Corporation media empire, which faced a series of damaging revelations during 2011 over phone hacking at its UK newspaper the News of the World.

GSK's chairman Sir Christopher Gent said: “James has taken this decision to focus on his current duties as non-executive chairman of BSkyB, and following his decision to re-locate to the US, as chairman and chief executive, international, of News Corporation.

“On behalf of the board, I would like to thank James for the very strong contribution he has made since he was appointed in 2009 and wish him well for the future.”

Other planned changes to GSK's board will see Sir Crispin Davis, Sir Robert Wilson and Larry Culp step down in 2013.

Sir Crispin will be succeeded by Tom de Swaan, who will take over as chairman of the remuneration committee with effect from January 1, 2013, and Judy Lewent, who will take over as chair of the audit and risk committee with effect from the same date.

Meanwhile Sir Deryck Maughan will succeed Sir Robert as senior independent non-executive director with effect from the closure of GSK's annual general meeting in 2013.

31st January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics